Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA regroups on BPA

This article was originally published in The Tan Sheet

Executive Summary

FDA says Oct. 28 it plans to research and address the potential low-dose effects of bisphenol A, which is used in packaging for some infant formula and food products. The Science Board on Oct. 31 asked the agency to reconsider its finding that current levels of BPA that transfer to foods and are absorbed by children are safe. The board recommended this after its BPA subcommittee reported FDA overlooked multiple studies that it should have considered. Before FDA's advisory board rendered its opinion, a Journal of American Medical Association study concluded higher concentrations of BPA in human urine are associated with cardiovascular disease, diabetes and liver-enzyme abnormalities. The JAMA study prompted Congress to criticize FDA's conclusion (1"The Tan Sheet" Oct. 13, 2008, In Brief)
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS102280

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel